Antibacterial Therapies Drug Development Pipeline Review, 2017

  • ID: 4191540
  • Report
  • Region: Global
  • 418 Pages
  • GBI Research
1 of 5
There are Over 1400 Products in Active Development in the Antibacterial Drug Market, with the Majority of Products Being Small Molecules

FEATURED COMPANIES

  • Abera Bioscience AB,
  • BioDiem Ltd,
  • Crestone, Inc.,
  • EpiVax, Inc.,
  • Hager Biosciences, LLC,
  • Johnson & Johnson,
  • MORE

The antibacterial drug market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market.

There are over 1400 products in active development in the antibacterial drug market, with the majority of products being small molecules. Vaccines are also well established within the market, and accounts for approximately 25% of the pipeline.

Currently, drugs for the prevention of bacterial infections are typically vaccines which help to train the body’s immune system to fight off bacterial infections caused by specific bacterial strains. However, several prophylactic monoclonal antibodies are now in the pipeline and may impact the market in the near future.

Drugs for the treatment of bacterial infections are slightly more varied. Most common are beta-lactam antibiotics, such as penicillin, and protein synthesis inhibitors. However, bacterial resistance has reduced the efficacy of many of these drugs. As a result the pipeline includes a variety of new-generation protein synthesis inhibitors and beta-lactam/beta-lactamase inhibitor combination drugs, which are active against currently hard to treat bacterial strains.

The report provides comprehensive information on the pipeline development landscape for Pneumonia, Methicillin-resistant staphylococcus aureus (MRSA) and Tuberculosis, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Scope

  • Which companies are the most active within the pipeline for antibacterial drugs?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abera Bioscience AB,
  • BioDiem Ltd,
  • Crestone, Inc.,
  • EpiVax, Inc.,
  • Hager Biosciences, LLC,
  • Johnson & Johnson,
  • MORE

1. Introduction

2. Research Report Coverage

3. Tuberculosis Overview

  • Pneumonia
  • Methicillin-Resistant Staphylococcus aureus (MRSA)

4. Therapeutics Development

  • Tuberculosis
  • Pneumonia
  • Methicillin-Resistant Staphylococcus aureus (MRSA)

5. Therapeutics under Development by Companies

  • Tuberculosis
  • Pneumonia
  • Methicillin-Resistant Staphylococcus aureus (MRSA)

6. Therapeutics under Investigation by Universities/Institutes

  • Tuberculosis
  • Pneumonia
  • Methicillin-Resistant Staphylococcus aureus (MRSA)

7. Pipeline Products Glance

  • Tuberculosis
  • Pneumonia
  • Methicillin-Resistant Staphylococcus aureus (MRSA)

8. Products under Development by Companies

  • Tuberculosis
  • Pneumonia
  • Methicillin-Resistant Staphylococcus aureus (MRSA)

9. Products under Investigation by Universities/Institutes

  • Tuberculosis
  • Pneumonia
  • Methicillin-Resistant Staphylococcus aureus (MRSA)

10. Companies Involved in Therapeutics Development

  • Tuberculosis
  • Pneumonia
  • Methicillin-Resistant Staphylococcus aureus (MRSA)

11. Therapeutics Assessment

  • Tuberculosis
  • Pneumonia
  • Methicillin-Resistant Staphylococcus aureus (MRSA)

12. Dormant Projects

  • Tuberculosis
  • Pneumonia
  • Methicillin-Resistant Staphylococcus aureus (MRSA)

13. Discontinued Products

  • Tuberculosis
  • Pneumonia
  • Methicillin-Resistant Staphylococcus aureus (MRSA)

14. Product Development Milestones

  • Tuberculosis
  • Pneumonia
  • Methicillin-Resistant Staphylococcus aureus (MRSA)

15. Appendix

  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation

List of Tables

  • Number of Products under Development for Tuberculosis
  • Number of Products under Development for Tuberculosis - Comparative Analysis
  • Number of Products under Development for Community Acquired Pneumonia
  • Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis
  • Number of Products under Development for Hospital Acquired Pneumonia (HAP)
  • Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis
  • Number of Products under Development for Ventilator Associated Pneumonia (VAP)
  • Number of Products under Development for Ventilator Associated Pneumonia (VAP) - Comparative Analysis
  • Number of Products under Development for Pseudomonas aeruginosa Infections
  • Number of Products under Development for Pseudomonas aeruginosa Infections - Comparative Analysis
  • Number of Products under Development for Klebsiella pneumoniae Infections
  • Number of Products under Development for Klebsiella pneumoniae Infections - Comparative Analysis
  • Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Comparative Analysis
  • Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
  • Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Comparative Analysis
  • Number of Products under Development by Companies, Tuberculosis
  • Number of Products under Development by Companies, Community Acquired Pneumonia
  • Number of Products under Development by Companies, Hospital Acquired Pneumonia (HAP)
  • Number of Products under Development by Companies, Ventilator Associated Pneumonia (VAP)
  • Number of Products under Development by Companies, Pseudomonas aeruginosa Infections
  • Number of Products under Development by Companies, Klebsiella pneumoniae Infections
  • Number of Products under Development by Companies, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Number of Products under Development by Companies, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
  • Number of Products under Development by Companies, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Number of Products under Investigation by Universities/Institutes, Tuberculosis
  • Number of Products under Investigation by Universities/Institutes, Hospital Acquired Pneumonia (HAP)
  • Number of Products under Investigation by Universities/Institutes, Ventilator Associated Pneumonia (VAP)
  • Number of Products under Investigation by Universities/Institutes, Pseudomonas aeruginosa Infections
  • Number of Products under Investigation by Universities/Institutes, Klebsiella pneumoniae Infections
  • Number of Products under Investigation by Universities/Institutes, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Number of Products under Investigation by Universities/Institutes, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Comparative Analysis by Late Stage Development, Tuberculosis
  • Comparative Analysis by Clinical Stage Development, Tuberculosis
  • Comparative Analysis by Early Stage Development, Tuberculosis
  • Comparative Analysis by Unknown Stage Development, Tuberculosis
  • Comparative Analysis by Late Stage Development, Community Acquired Pneumonia
  • Comparative Analysis by Clinical Stage Development, Community Acquired Pneumonia
  • Comparative Analysis by Early Stage Development, Community Acquired Pneumonia
  • Comparative Analysis by Late Stage Development, Hospital Acquired Pneumonia (HAP)
  • Comparative Analysis by Clinical Stage Development, Hospital Acquired Pneumonia (HAP)
  • Comparative Analysis by Early Stage Development, Hospital Acquired Pneumonia (HAP)
  • Comparative Analysis by Unknown Stage Development, Hospital Acquired Pneumonia (HAP)
  • Comparative Analysis by Late Stage Development, Ventilator Associated Pneumonia (VAP)
  • Comparative Analysis by Clinical Stage Development, Ventilator Associated Pneumonia (VAP)
  • Comparative Analysis by Early Stage Development, Ventilator Associated Pneumonia (VAP)
  • Comparative Analysis by Unknown Stage Development, Ventilator Associated Pneumonia (VAP)
  • Comparative Analysis by Late Stage Development, Pseudomonas aeruginosa Infections
  • Comparative Analysis by Clinical Stage Development, Pseudomonas aeruginosa Infections
  • Comparative Analysis by Early Stage Development, Pseudomonas aeruginosa Infections
  • Comparative Analysis by Unknown Stage Development, Pseudomonas aeruginosa Infections
  • Comparative Analysis by Late Stage Development, Klebsiella pneumoniae Infections
  • Comparative Analysis by Clinical Stage Development, Klebsiella pneumoniae Infections
  • Comparative Analysis by Early Stage Development, Klebsiella pneumoniae Infections
  • Comparative Analysis by Late Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Comparative Analysis by Clinical Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Comparative Analysis by Early Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Comparative Analysis by Unknown Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Comparative Analysis by Clinical Stage Development, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
  • Comparative Analysis by Early Stage Development, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
  • Comparative Analysis by Clinical Stage Development, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Comparative Analysis by Early Stage Development, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Products under Development by Companies, Tuberculosis
  • Products under Development by Companies, Community Acquired Pneumonia
  • Products under Development by Companies, Hospital Acquired Pneumonia (HAP)
  • Products under Development by Companies, Ventilator Associated Pneumonia (VAP)
  • Products under Development by Companies, Pseudomonas aeruginosa Infections
  • Products under Development by Companies, Klebsiella pneumoniae Infections
  • Products under Development by Companies, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Products under Development by Companies, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
  • Products under Development by Companies, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Products under Investigation by Universities/Institutes, Tuberculosis
  • Products under Investigation by Universities/Institutes, Hospital Acquired Pneumonia (HAP)
  • Products under Investigation by Universities/Institutes, Ventilator Associated Pneumonia (VAP)
  • Products under Investigation by Universities/Institutes, Pseudomonas aeruginosa Infections
  • Products under Investigation by Universities/Institutes, Klebsiella pneumoniae Infections
  • Products under Investigation by Universities/Institutes, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Products under Investigation by Universities/Institutes, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Tuberculosis - Pipeline by Abera Bioscience AB,
  • Tuberculosis - Pipeline by Akthelia Pharmaceuticals Limited,
  • Tuberculosis - Pipeline by Alvogen Korea Co., Ltd.,
  • Tuberculosis - Pipeline by Anacor Pharmaceuticals, Inc.,
  • Tuberculosis - Pipeline by Archivel Farma S.L.,
  • Tuberculosis - Pipeline by AstraZeneca Plc,
  • Tuberculosis - Pipeline by Beech Tree Labs, Inc.,
  • Tuberculosis - Pipeline by BioDiem Ltd,
  • Tuberculosis - Pipeline by BioLingus AG,
  • Tuberculosis - Pipeline by Biomar Microbial Technologies,
  • Tuberculosis - Pipeline by Bioversys AG,
  • Tuberculosis - Pipeline by Celgene Corporation,
  • Tuberculosis - Pipeline by Cellceutix Corporation,
  • Tuberculosis - Pipeline by Chongqing Zhifei Biological Products Co., Ltd.,
  • Tuberculosis - Pipeline by Crestone, Inc.,
  • Tuberculosis - Pipeline by Dafra Pharma International Ltd.,
  • Tuberculosis - Pipeline by Daiichi Sankyo Company, Limited,
  • Tuberculosis - Pipeline by Demuris Limited,
  • Tuberculosis - Pipeline by Eisai Co., Ltd.,
  • Tuberculosis - Pipeline by Eli Lilly and Company,
  • Tuberculosis - Pipeline by Ensol Biosciences Inc.,
  • Tuberculosis - Pipeline by EpiVax, Inc.,
  • Tuberculosis - Pipeline by FIT Biotech Oy,
  • Tuberculosis - Pipeline by GangaGen Inc.,
  • Tuberculosis - Pipeline by GlaxoSmithKline Plc,
  • Tuberculosis - Pipeline by Globeimmune, Inc.,
  • Tuberculosis - Pipeline by Hager Biosciences, LLC,
  • Tuberculosis - Pipeline by Hsiri Therapeutics LLC,
  • Tuberculosis - Pipeline by Imaxio SA,
  • Tuberculosis - Pipeline by Immunitor, Inc.,
  • Tuberculosis - Pipeline by ImmunoBiology Limited,
  • Tuberculosis - Pipeline by Inovio Pharmaceuticals, Inc.,
  • Tuberculosis - Pipeline by Johnson & Johnson,
  • Tuberculosis - Pipeline by Lakewood-Amedex Inc,
  • Tuberculosis - Pipeline by Lipotek Pty Ltd.,
  • Tuberculosis - Pipeline by Matinas BioPharma Holdings, Inc. ,
  • Tuberculosis - Pipeline by Microbion Corporation,
  • Tuberculosis - Pipeline by Microbiotix, Inc.,
  • Tuberculosis - Pipeline by NEARMEDIC PLUS, Ltd,
  • Tuberculosis - Pipeline by Novartis AG,
  • Tuberculosis - Pipeline by NovoBiotic Pharmaceuticals, LLC,
  • Tuberculosis - Pipeline by Otsuka Holdings Co., Ltd.,
  • Tuberculosis - Pipeline by QureTech Bio AB,
  • Tuberculosis - Pipeline by Recce Pty Ltd,
  • Tuberculosis - Pipeline by Rodos BioTarget GmbH

List of Figures

  • Number of Products under Development for Tuberculosis
  • Number of Products under Development for Tuberculosis - Comparative Analysis
  • Number of Products under Development for Community Acquired Pneumonia
  • Number of Products under Development for Hospital Acquired Pneumonia (HAP)
  • Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis
  • Number of Products under Development for Ventilator Associated Pneumonia (VAP)
  • Number of Products under Development for Ventilator Associated Pneumonia (VAP) - Comparative Analysis
  • Number of Products under Development for Pseudomonas aeruginosa Infections
  • Number of Products under Development for Pseudomonas aeruginosa Infections - Comparative Analysis
  • Number of Products under Development for Klebsiella pneumoniae Infections
  • Number of Products under Development for Klebsiella pneumoniae Infections - Comparative Analysis
  • Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Comparative Analysis
  • Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
  • Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Comparative Analysis
  • Number of Products under Development by Companies, Tuberculosis
  • Number of Products under Development by Companies, Community Acquired Pneumonia
  • Number of Products under Development by Companies, Hospital Acquired Pneumonia (HAP)
  • Number of Products under Development by Companies, Ventilator Associated Pneumonia (VAP)
  • Number of Products under Development by Companies, Pseudomonas aeruginosa Infections
  • Number of Products under Development by Companies, Klebsiella pneumoniae Infections
  • Number of Products under Development by Companies, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Number of Products under Development by Companies, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
  • Number of Products under Development by Companies, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Number of Products under Investigation by Universities/Institutes, Tuberculosis
  • Number of Products under Investigation by Universities/Institutes, Pseudomonas aeruginosa Infections
  • Number of Products under Investigation by Universities/Institutes, Klebsiella pneumoniae Infections
  • Number of Products under Investigation by Universities/Institutes, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Comparative Analysis by Late Stage Development, Tuberculosis
  • Comparative Analysis by Clinical Stage Development, Tuberculosis
  • Comparative Analysis by Early Stage Products, Tuberculosis
  • Comparative Analysis by Late Stage Development, Community Acquired Pneumonia
  • Comparative Analysis by Clinical Stage Development, Community Acquired Pneumonia
  • Comparative Analysis by Early Stage Products, Community Acquired Pneumonia
  • Comparative Analysis by Clinical Stage Development, Hospital Acquired Pneumonia (HAP)
  • Comparative Analysis by Early Stage Products, Hospital Acquired Pneumonia (HAP)
  • Comparative Analysis by Late Stage Development, Ventilator Associated Pneumonia (VAP)
  • Comparative Analysis by Clinical Stage Development, Ventilator Associated Pneumonia (VAP)
  • Comparative Analysis by Early Stage Products, Ventilator Associated Pneumonia (VAP)
  • Comparative Analysis by Unknown Stage Development, Ventilator Associated Pneumonia (VAP)
  • Comparative Analysis by Late Stage Development, Pseudomonas aeruginosa Infections
  • Comparative Analysis by Clinical Stage Development, Pseudomonas aeruginosa Infections
  • Comparative Analysis by Early Stage Products, Pseudomonas aeruginosa Infections
  • Comparative Analysis by Unknown Stage Development, Pseudomonas aeruginosa Infections
  • Comparative Analysis by Early Stage Products, Klebsiella pneumoniae Infections
  • Comparative Analysis by Clinical Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Comparative Analysis by Early Stage Products, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Comparative Analysis by Early Stage Products, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Assessment by Monotherapy Products, Tuberculosis
  • Assessment by Combination Products, Tuberculosis
  • Number of Products by Top 10 Targets, Tuberculosis
  • Number of Products by Stage and Top 10 Targets, Tuberculosis
  • Number of Products by Top 10 Mechanism of Actions, Tuberculosis
  • Number of Products by Stage and Top 10 Mechanism of Actions, Tuberculosis
  • Number of Products by Top 10 Routes of Administration, Tuberculosis
  • Number of Products by Stage and Top 10 Routes of Administration, Tuberculosis
  • Number of Products by Top 10 Molecule Types, Tuberculosis
  • Number of Products by Stage and Top 10 Molecule Types, Tuberculosis
  • Assessment by Monotherapy Products, Community Acquired Pneumonia
  • Number of Products by Targets, Community Acquired Pneumonia
  • Number of Products by Stage and Targets, Community Acquired Pneumonia
  • Number of Products by Mechanism of Actions, Community Acquired Pneumonia
  • Number of Products by Stage and Mechanism of Actions, Community Acquired Pneumonia
  • Number of Products by Routes of Administration, Community Acquired Pneumonia
  • Number of Products by Stage and Routes of Administration, Community Acquired Pneumonia
  • Number of Products by Molecule Types, Community Acquired Pneumonia
  • Number of Products by Stage and Top 10 Molecule Types, Community Acquired Pneumonia
  • Assessment by Monotherapy Products, Hospital Acquired Pneumonia (HAP)
  • Assessment by Combination Products, Hospital Acquired Pneumonia (HAP)
  • Number of Products by Top 10 Targets, Hospital Acquired Pneumonia (HAP)
  • Number of Products by Stage and Top 10 Targets, Hospital Acquired Pneumonia (HAP)
  • Number of Products by Top 10 Mechanism of Actions, Hospital Acquired Pneumonia (HAP)
  • Number of Products by Stage and Top 10 Mechanism of Actions, Hospital Acquired Pneumonia (HAP)
  • Number of Products by Routes of Administration, Hospital Acquired Pneumonia (HAP)
  • Number of Products by Stage and Routes of Administration, Hospital Acquired Pneumonia (HAP)
  • Number of Products by Molecule Types, Hospital Acquired Pneumonia (HAP)
  • Number of Products by Stage and Molecule Types, Hospital Acquired Pneumonia (HAP)
  • Assessment by Monotherapy Products, Ventilator Associated Pneumonia (VAP)
  • Assessment by Combination Products, Ventilator Associated Pneumonia (VAP)
  • Number of Products by Top 10 Targets, Ventilator Associated Pneumonia (VAP)
  • Number of Products by Stage and Top 10 Targets, Ventilator Associated Pneumonia (VAP)
  • Number of Products by Top 10 Mechanism of Actions, Ventilator Associated Pneumonia (VAP)
  • Number of Products by Stage and Top 10 Mechanism of Actions, Ventilator Associated Pneumonia (VAP)
  • Number of Products by Top 10 Routes of Administration, Ventilator Associated Pneumonia (VAP)
  • Number of Products by Stage and Top 10 Routes of Administration, Ventilator Associated Pneumonia (VAP)
  • Number of Products by Top 10 Molecule Types, Ventilator Associated Pneumonia (VAP)
  • Number of Products by Stage and Top 10 Molecule Types, Ventilator Associated Pneumonia (VAP)
  • Assessment by Monotherapy Products, Pseudomonas aeruginosa Infections
  • Assessment by Combination Products, Pseudomonas aeruginosa Infections
  • Number of Products by Top 10 Targets, Pseudomonas aeruginosa Infections
  • Number of Products by Stage and Top 10 Targets, Pseudomonas aeruginosa Infections
  • Number of Products by Top 10 Mechanism of Actions, Pseudomonas aeruginosa Infections
  • Number of Products by Stage and Top 10 Mechanism of Actions, Pseudomonas aeruginosa Infections
  • Number of Products by Routes of Administration, Pseudomonas aeruginosa Infections
  • Number of Products by Stage and Routes of Administration, Pseudomonas aeruginosa Infections
  • Number of Products by Top 10 Molecule Types, Pseudomonas aeruginosa Infections
  • Number of Products by Stage and Top 10 Molecule Types, Pseudomonas aeruginosa Infections
  • Assessment by Monotherapy Products, Klebsiella pneumoniae Infections
  • Number of Products by Top 10 Targets, Klebsiella pneumoniae Infections
  • Number of Products by Stage and Top 10 Targets, Klebsiella pneumoniae Infections
  • Number of Products by Top 10 Mechanism of Actions, Klebsiella pneumoniae Infections
  • Number of Products by Stage and Top 10 Mechanism of Actions, Klebsiella pneumoniae Infections
  • Number of Products by Routes of Administration, Klebsiella pneumoniae Infections
  • Number of Products by Stage and Routes of Administration, Klebsiella pneumoniae Infections
  • Number of Products by Molecule Types, Klebsiella pneumoniae Infections
  • Number of Products by Stage and Molecule Types, Klebsiella pneumoniae Infections
  • Assessment by Monotherapy Products, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Assessment by Combination Products, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Number of Products by Top 10 Targets, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Number of Products by Stage and Top 10 Targets, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Number of Products by Top 10 Mechanism of Actions, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Number of Products by Stage and Top 10 Mechanism of Actions, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Number of Products by Top 10 Routes of Administration, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Number of Products by Stage and Top 10 Routes of Administration, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Number of Products by Top 10 Molecule Types, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Number of Products by Stage and Top 10 Molecule Types, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections
  • Assessment by Monotherapy Products, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
  • Number of Products by Targets, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
  • Number of Products by Stage and Targets, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
  • Number of Products by Mechanism of Actions, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
  • Number of Products by Stage and Mechanism of Actions, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
  • Number of Products by Routes of Administration, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
  • Number of Products by Stage and Routes of Administration, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
  • Number of Products by Molecule Types, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
  • Number of Products by Stage and Molecule Types, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections
  • Assessment by Monotherapy Products, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Number of Products by Targets, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Number of Products by Stage and Targets, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Number of Products by Top 10 Mechanism of Actions, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Number of Products by Stage and Top 10 Mechanism of Actions, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Number of Products by Routes of Administration, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Number of Products by Stage and Routes of Administration, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Number of Products by Molecule Types, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
  • Number of Products by Stage and Molecule Types, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abera Bioscience AB,
  • Akthelia Pharmaceuticals Limited,
  • Alvogen Korea Co., Ltd.,
  • Anacor Pharmaceuticals, Inc.,
  • Archivel Farma S.L.,
  • AstraZeneca Plc,
  • Beech Tree Labs, Inc.,
  • BioDiem Ltd,
  • BioLingus AG,
  • Biomar Microbial Technologies,
  • Bioversys AG,
  • Celgene Corporation,
  • Cellceutix Corporation,
  • Chongqing Zhifei Biological Products Co., Ltd.,
  • Crestone, Inc.,
  • Dafra Pharma International Ltd.,
  • Daiichi Sankyo Company, Limited,
  • Demuris Limited,
  • Eisai Co., Ltd.,
  • Eli Lilly and Company,
  • Ensol Biosciences Inc.,
  • EpiVax, Inc.,
  • FIT Biotech Oy,
  • GangaGen Inc.,
  • GlaxoSmithKline Plc,
  • Globeimmune, Inc.,
  • Hager Biosciences, LLC,
  • Hsiri Therapeutics LLC,
  • Imaxio SA,
  • Immunitor, Inc.,
  • ImmunoBiology Limited,
  • Inovio Pharmaceuticals, Inc.,
  • Johnson & Johnson,
  • Lakewood-Amedex Inc,
  • Lipotek Pty Ltd.,
  • Matinas BioPharma Holdings, Inc. ,
  • Microbion Corporation,
  • Microbiotix, Inc.,
  • NEARMEDIC PLUS, Ltd,
  • Novartis AG,
  • NovoBiotic Pharmaceuticals, LLC,
  • Otsuka Holdings Co., Ltd.,
  • QureTech Bio AB,
  • Recce Pty Ltd,
  • Rodos BioTarget GmbH
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll